{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:56Z","timestamp":1793392736553,"version":"4.5.0"},"reference-count":44,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MERZ France"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Spasticity is one of the most disabling symptoms in multiple sclerosis (MS). Botulinum toxin injection (BTI) is a first-line treatment for focal spasticity. There is a lack of evidence of a functional improvement following BTI in MS-related spasticity. To describe goal-setting for BTI in MS, and evaluate the degree of attainment, using goal attainment scaling (GAS) 4-to-6 weeks after injection session, a one-year multi-center retrospective observational study assessing goal-setting and achievement during BTI session in spastic patients with MS was set up. Following the GAS method, patients and their physicians set up to three goals and scored their achievement 4 to 6 weeks thereafter. Commonly used goals from three centers were combined into a standardized list and 125 single BTI sessions were analyzed. The most frequent goals regarded lower limb (LL) impairments (equinovarus foot, toe claw) or locomotion (stability, walking distance, clinging) and accounted for 89.1%, versus 10.9% for upper limb (UL), mostly for mild-to-moderate MS. Overall, goals were frequently achieved (85.77%) mainly when related to gait and mobility rather than hygiene and ease of care. This study gives an overview on the most frequent, relevant, and achievable goals to be set in real-life practice of BTI for spasticity management in MS.<\/jats:p>","DOI":"10.3390\/toxins14090582","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T01:50:26Z","timestamp":1661392226000},"page":"582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Ines","family":"Baccouche","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Raymond-Poincar\u00e9 University Hospital, AP-HP, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"},{"name":"Fondation Garches, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamel","family":"Bensmail","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Raymond-Poincar\u00e9 University Hospital, AP-HP, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"},{"name":"Fondation Garches, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Leblong","sequence":"additional","affiliation":[{"name":"P\u00f4le MPR St. H\u00e9lier\u2014Living Lab ISAR, 54 Rue St. H\u00e9lier, CEDEX, 35043 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Fraudet","sequence":"additional","affiliation":[{"name":"P\u00f4le MPR St. H\u00e9lier\u2014Living Lab ISAR, 54 Rue St. H\u00e9lier, CEDEX, 35043 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Aymard","sequence":"additional","affiliation":[{"name":"Fondation Sainte Marie Paris, 167 Rue Raymond Losserand, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorine","family":"Quintaine","sequence":"additional","affiliation":[{"name":"Fondation Sainte Marie Paris, 167 Rue Raymond Losserand, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pottier","sequence":"additional","affiliation":[{"name":"Fondation Garches, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Lansaman","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Raymond-Poincar\u00e9 University Hospital, AP-HP, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Malot","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Raymond-Poincar\u00e9 University Hospital, AP-HP, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gallien","sequence":"additional","affiliation":[{"name":"P\u00f4le MPR St. H\u00e9lier\u2014Living Lab ISAR, 54 Rue St. H\u00e9lier, CEDEX, 35043 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-0724","authenticated-orcid":false,"given":"Jonathan","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Raymond-Poincar\u00e9 University Hospital, AP-HP, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"},{"name":"Fondation Garches, 104 Blvd Raymond Poincar\u00e9, 92380 Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: Current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"Eur. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1177\/13524585221105465","article-title":"The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials","volume":"28","author":"Strijbis","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1212\/WNL.30.12.1303","article-title":"The Control of muscle tone, reflexes, and movement: Robert Wartenberg lecture","volume":"30","author":"Lance","year":"1980","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09638280400014576","article-title":"Spasticity: Clinical perceptions, neurological realities and meaningful measurement","volume":"27","author":"Pandyan","year":"2005","journal-title":"Disabil. Rehabil."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult. Scler."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11940-017-0470-5","article-title":"Botulinum toxin treatment in multiple sclerosis\u2014A review","volume":"19","author":"Safarpour","year":"2017","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/NPT.0b013e31822a8c40","article-title":"Influence of spasticity on mobility and balance in persons with multiple sclerosis","volume":"35","author":"Sosnoff","year":"2011","journal-title":"J. Neurol. Phys. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0035-3787(12)70046-2","article-title":"Epidemiology and clinical assessment of spasticity in multiple sclerosis","volume":"168","author":"Bensmail","year":"2012","journal-title":"Rev. Neurol."},{"key":"ref_10","unstructured":"Food and Drug Administration (2021, September 07). BOTOX (OnabotulinumtoxinA) for Injection, for Intramuscular, Intradetrusor, or Intradermal Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103000s5318lbl.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.410280407","article-title":"Treatment of spasticity with botulinum toxin: A double-blind study","volume":"28","author":"Snow","year":"1990","journal-title":"Ann. Neurol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.45.4.712","article-title":"Botulinum toxin A for spasticity, muscle spasms, and rigidity","volume":"45","author":"Grazko","year":"1995","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","article-title":"Botulinum toxin (dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study","volume":"68","author":"Hyman","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0269215513480956","article-title":"Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial","volume":"27","author":"Paoloni","year":"2013","journal-title":"Clin. Rehabil."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0269215507072772","article-title":"Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis","volume":"21","author":"Giovannelli","year":"2007","journal-title":"Clin. Rehabil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01354.x","article-title":"Efficacy and safety of NT 201 for upper limb spasticity of various etiologies\u2014A randomized parallel-group study: NT 201 in upper limb spasticity","volume":"122","author":"Barnes","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.rehab.2018.05.1320","article-title":"Does botulinum toxin treatment improve upper limb active function?","volume":"62","author":"Levy","year":"2019","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/09638280801906388","article-title":"Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes","volume":"31","author":"Ashford","year":"2009","journal-title":"Disabil. Rehabil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e002230","DOI":"10.1136\/bmjopen-2012-002230","article-title":"Upper limb international spasticity study: Rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice","volume":"3","author":"Fheodoroff","year":"2013","journal-title":"BMJ Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"jrm00157","DOI":"10.2340\/16501977-2801","article-title":"Upper limb international spasticity (ULIS-III) study group longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational upper limb international spasticity (ULIS-III) cohort study","volume":"53","author":"Jacinto","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3390\/toxins7041192","article-title":"Factors influencing goal attainment in patients with post-stroke upper limb spasticity following treatment with botulinum toxin A in real-life clinical practice: Sub-analyses from the upper limb international spasticity (ULIS)-II study","volume":"7","author":"Fheodoroff","year":"2015","journal-title":"Toxins"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"jrm00133","DOI":"10.2340\/16501977-2770","article-title":"Upper limb international spasticity-III (ULIS-III) study group assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III study","volume":"53","author":"Jacinto","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/pri.1554","article-title":"Systematic review of upper-limb function measurement methods in botulinum toxin intervention for focal spasticity","volume":"18","author":"Ashford","year":"2013","journal-title":"Physiother. Res. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.rehab.2013.02.002","article-title":"Goal attainment scaling in rehabilitation: A literature-based update","volume":"56","author":"Hiebel","year":"2013","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01530764","article-title":"Goal attainment scaling: A general method for evaluating comprehensive community mental health programs","volume":"4","author":"Kiresuk","year":"1968","journal-title":"Community Ment. Health J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269215508101742","article-title":"Goal attainment scaling (GAS) in rehabilitation: A practical guide","volume":"23","year":"2009","journal-title":"Clin. Rehabil."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pri.36","article-title":"Goal attainment for spasticity management using botulinum toxin","volume":"11","author":"Ashford","year":"2006","journal-title":"Physiother. Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.apmr.2015.08.424","article-title":"Proposed criteria for appraising goal attainment scales used as outcome measures in rehabilitation research","volume":"97","author":"Evans","year":"2016","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rehab.2017.01.005","article-title":"Feasibility of a shorter goal attainment scaling method for a pediatric spasticity clinic\u2014The 3-milestones GAS","volume":"60","author":"Pauly","year":"2017","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.physio.2014.04.001","article-title":"Goal setting, using goal attainment scaling, as a method to identify patient selected items for measuring arm function","volume":"101","author":"Ashford","year":"2015","journal-title":"Physiotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e011157","DOI":"10.1136\/bmjopen-2016-011157","article-title":"Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: Rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III)","volume":"6","author":"Ashford","year":"2016","journal-title":"BMJ Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/qjmed\/hch105","article-title":"What drives quality of life in multiple sclerosis?","volume":"97","author":"Hemmett","year":"2004","journal-title":"QJM An. Int. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pmr.2013.07.002","article-title":"Gait impairment and optimizing mobility in multiple sclerosis","volume":"24","author":"Stevens","year":"2013","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/1545968308328724","article-title":"Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity","volume":"23","author":"Bensmail","year":"2009","journal-title":"Neurorehabil. Neural. Repair"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1799","DOI":"10.1002\/pri.1799","article-title":"Spasticity, gait, and balance in patients with multiple sclerosis: A cross-sectional study","volume":"25","author":"Norbye","year":"2020","journal-title":"Physiother. Res. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0269215508101741","article-title":"Writing SMART rehabilitation goals and achieving goal attainment scaling: A practical guide","volume":"23","author":"Botell","year":"2009","journal-title":"Clin. Rehabil."},{"key":"ref_38","first-page":"605","article-title":"A comprehensive person-centred approach to adult spastic paresis: A consensus-based framework","volume":"54","author":"Ashford","year":"2017","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2340\/16501977-0002","article-title":"Use of International classification of functioning, disability and health (ICF) to describe patient-reported disability in multiple sclerosis and identification of relevant environmental factors","volume":"39","author":"Khan","year":"2007","journal-title":"J. Rehabil. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.apmr.2007.09.049","article-title":"Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis","volume":"89","author":"Khan","year":"2008","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.rehab.2009.09.005","article-title":"Drug treatments for spasticity","volume":"52","author":"Yelnik","year":"2009","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys. Ther."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/9\/582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:33Z","timestamp":1760141673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/9\/582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["toxins14090582"],"URL":"https:\/\/doi.org\/10.3390\/toxins14090582","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}